Cancer Therapeutics & Host Response Program Co-Leaders » Cancer Center » UF Health Cancer Center

Christian Jobin Ph.D.

Professor Of Medicine; Principal Investigator

Department: MD-GASTROENTEROLOGY

Mailing Address:: CGRC-461
CGRC-461
2033 MOWRY RD
GAINESVILLE FL 326100001

Physical Address:: 2033 MOWRY RD
GAINESVILLE FL 32611

Accomplishments:

Associate Editor
2017-2020 · Microbiome
Chair study section for Program Project Grant exploring the metabolic, epigenetic and microbiome drivers of inflammation driven malignancy
2017 · Terry Fox Research Institute
Permanent Member
2015-2020 · NIH GMPB
UF Senior Faculty Excellence in Research Award
2015 · University of Florida
Study Section Memberships – Advisory Board
2014-2016 · CIHR Institute Advisory Board of Infection and Immunity
Study Section Memberships -Advisory Board
2014-2015 · American Society for Cancer
Study Section Memberships – Advisory Board
2014-2015 · AICR
Study Section Memberships – Advisory Board
2013-2020 · NIH NCI Chair ZRG1 DKUS-D: Role of the Microflora in the Etiology of Gastrointestinal Cancer
Study Section Memberships – Advisory Board
2011-2020 · Ad Hoc NIH Gastrointestinal Mucosal Pathobiology (GMBP)
Study Section Memberships – Advisory Board
2010-2013 · Canadian Institutes of Health Research, Vanier Canada Graduate Scholarships
Admission Committee
2009-2012 · UNC Biological and Biomedical Sciences Program
IBD: Associate Editor
2008-2016 · Cell Biology/Biochemistry/Molecular Biology
Study Section Memberships – Advisory Board
2008-2011 · CCFA Study section (Fellowship and Career Awards)
Study Section
2007-2020 · NIH Tumor Microenvironment (TME)
IBD: Section Editor
2007-2008 · Cell Biology/Biochemistry/Molecular Biology
Editorial Board Member
2005-2010 · Gastroenterology
Junior Faculty Development Award
2005 · UNC
Fireman Young Scientist Basic Research Award
2005 · American Gastroenterological Association
University Research Council Award
2004 · Mucosal Immunology Society
Study Section Memberships – Advisory Board
2003-2007 · Canadian Institutes of Health Research, Experimental Medicine
Study Section Memberships – Advisory Board
2002-2020 · Ad Hoc NIH Special Emphasis Panel NIDDK
Editorial Board Member
2001-2009 · American Journal of Physiology
Young investigator travel award
1999 · Mucosal Immunology
Anne Ferguson Award
1999 · Mucosal Immunology Society
Career Development Award
1998-1999 · CCFA
University Research Council Award
1998 · University Research Council Award
CCFA Young IBD Investigator Award
1998 · “Regulation and modulation of the IkB/NF-kB transcriptional system in intestinal epithelial cells”
CCFA young investigator travel award
1996 · “Immune/non-immune cell interaction in intestinal inflammation” meeting in Florida
CCFA young investigator travel award
1995 · “Interactions between genetics and microbiology in inflammatory bowel disease” meeting in South Carolina
Ph.D fellowships
1991-1993 · Laval University
Ph.D fellowship
1990-1991 · Hôpital Saint-François d’Assise

Publications:

2024
Metabolic immaturity and breastmilk bile acid metabolites are central determinants of heightened newborn vulnerability to norovirus diarrhea.
Cell host & microbe
2024
Effect of Routine Gastric Residual Aspiration on the Preterm Infant Fecal Microbiome.
American journal of perinatology
2024
Correlation between intestinal microbiota and urolithin metabolism in a human walnut dietary intervention.
BMC microbiology
2024
Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer.
European urology oncology
2024
Chemotherapy-induced microbiota exacerbates the toxicity of chemotherapy through the suppression of interleukin-10 from macrophages.
Gut microbes
2024
Campylobacter jejuni-derived cytolethal distending toxin promotes colorectal cancer metastasis
Cell Host & Microbe
2024
Association between gut microbiota and CpG island methylator phenotype in colorectal cancer
Gut Microbes
2024
Antibiotic-Induced Gut Microbiota Dysbiosis Modulates Host Transcriptome and m6A Epitranscriptome via Bile Acid Metabolism.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2023
Western diet influences on microbiome and carcinogenesis.
Seminars in immunology
2023
The microbial genotoxin colibactin exacerbates mismatch repair mutations in colorectal tumors.
Neoplasia (New York, N.Y.)
2023
Skin microbiome sampling in the preterm neonate.
Pediatric dermatology
2023
Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer.
The Prostate
2023
Non-pathogenic microbiota accelerate age-related CpG Island methylation in colonic mucosa.
Epigenetics
2023
Microbiota Influences on Hematopoiesis and Blood Cancers: New Horizons?
Blood cancer discovery
2023
Intestinal bacteria and colorectal cancer: etiology and treatment.
Gut microbes
2023
Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer.
The Journal of experimental medicine
2022
The microbiome, gastrointestinal cancer, and immunotherapy.
Journal of gastroenterology and hepatology
2022
NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD.
Gut
2022
MarZIC: A Marginal Mediation Model for Zero-Inflated Compositional Mediators with Applications to Microbiome Data.
Genes
2022
Intestinal microbiota modulates pancreatic carcinogenesis through intratumoral natural killer cells.
Gut microbes
2022
Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
Genome medicine
2022
Human Colon Cancer-Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice.
Cancer discovery
2022
Gut Microbiota as a Novel Tool to Dissect the Complex Structures of Black Tea Polymers.
Journal of agricultural and food chemistry
2022
Group 3 innate lymphoid cell pyroptosis represents a host defence mechanism against Salmonella infection.
Nature microbiology
2022
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1).
Neoplasia (New York, N.Y.)
2022
Finding clues in unexpected places: detection of pancreatic cancer through the faecal microbiome.
Gut
2022
Bacteriophage-mediated manipulations of microbiota in gastrointestinal diseases.
Frontiers in microbiology
2021
The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort.
Gut microbes
2021
Shining a Light on Colibactin Biology.
Toxins
2021
Mitochondrial transcription factor A in RORγt+ lymphocytes regulate small intestine homeostasis and metabolism.
Nature communications
2021
Microbiota phylogenic analysis revealed decreased abundance of Faecalibacterium prausnitzii, an anti-inflammatory commensal bacterium, in patients with chronic graft-versus-host disease.
Hematology/oncology and stem cell therapy
2021
Microbiota in mesenteric adipose tissue from Crohn's disease promote colitis in mice.
Microbiome
2021
Microbiome-Derived Liquid Biopsy: New Hope for Cancer Screening?
Clinical chemistry
2021
Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.
The American journal of gastroenterology
2021
Implications of the microbiome in the development and treatment of pancreatic cancer: Thinking outside of the box by looking inside the gut.
Neoplasia (New York, N.Y.)
2021
IFAA: Robust Association Identification and Inference for Absolute Abundance in Microbiome Analyses.
Journal of the American Statistical Association
2021
Gut Microbiota Dysbiosis Associated with Persistent Fatigue in Hematopoietic Cell Transplantation Survivors.
Transplantation and cellular therapy
2021
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
Science (New York, N.Y.)
2021
Black Tea Theaflavin Detoxifies Metabolic Toxins in the Intestinal Tract of Mice.
Molecular nutrition & food research
2021
Bacterial Swarmers Enriched During Intestinal Stress Ameliorate Damage.
Gastroenterology
2021
Bacteria break barrier to promote metastasis.
Cancer cell
2021
Avenanthramide Metabotype from Whole-Grain Oat Intake is Influenced by Faecalibacterium prausnitzii in Healthy Adults.
The Journal of nutrition
2020
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View.
Trends in cancer
2020
Seaweed natural products modify the host inflammatory response via Nrf2 signaling and alter colon microbiota composition and gene expression.
Free radical biology & medicine
2020
Oral therapy with colonization factor antigen I prevents development of type 1 diabetes in Non-obese Diabetic mice.
Scientific reports
2020
Microbiota in pancreatic health and disease: the next frontier in microbiome research.
Nature reviews. Gastroenterology & hepatology
2020
Human Colon Mucosal Biofilms and Murine Host Communicate via Altered mRNA and microRNA Expression during Cancer.
mSystems
2020
Gut microbiota maturation during early human life induces enterocyte proliferation via microbial metabolites.
BMC microbiology
2020
Far reach of Fusobacterium nucleatum in cancer metastasis.
Gut
2020
Dietary iron variably modulates assembly of the intestinal microbiota in colitis-resistant and colitis-susceptible mice.
Gut microbes
2020
Characterization of the bacterial microbiome among free-ranging bottlenose dolphins (Tursiops truncatus).
Heliyon
2020
Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2020
Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer.
Nature cancer
2020
A mutational signature that can be made by a bacterium arises in human colon cancer.
Nature
2019
Yersiniabactin-Producing Adherent/Invasive Escherichia coli Promotes Inflammation-Associated Fibrosis in Gnotobiotic Il10-/- Mice.
Infection and immunity
2019
Microbiota facilitates the formation of the aminated metabolite of green tea polyphenol (-)-epigallocatechin-3-gallate which trap deleterious reactive endogenous metabolites.
Free radical biology & medicine
2019
Microbiota and cancer immunotherapy: in search of microbial signals.
Gut
2019
Microbial Colonization Coordinates the Pathogenesis of a Klebsiella pneumoniae Infant Isolate.
Scientific reports
2019
International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis.
Gut
2019
Initial microbial community of the neonatal stomach immediately after birth.
Gut microbes
2019
Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic.
The Journal of clinical investigation
2019
Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection.
Gastroenterology
2019
Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin.
Gut
2018
Transcription factor Bcl11b is central for Th2 cell differentiation in asthma and immune response to helminths
Nature Communications
2018
Publisher Correction: Bcl11b is essential for licensing Th2 differentiation during helminth infection and allergic asthma.
Nature communications
2018
Precision medicine using microbiota.
Science (New York, N.Y.)
2018
Microbiota-Derived Metabolic Factors Reduce Campylobacteriosis in Mice.
Gastroenterology
2018
Microbial networking in cancer: when two toxins collide.
British journal of cancer
2018
Microbial dysbiosis associated with impaired intestinal Na+/H+ exchange accelerates and exacerbates colitis in ex-germ free mice.
Mucosal immunology
2018
Microbial dysbiosis associated with impaired intestinal Na+/H+ exchange accelerates and exacerbates colitis in ex germ free mice
Mucosal Immunology
2018
Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models.
Carcinogenesis
2018
Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex.
Vaccine
2018
Colorectal cancer: Hand-in-hand – colorectal cancer metastasizes with microorganisms.
Nature reviews. Gastroenterology & hepatology
2018
Bcl11b is essential for licensing Th2 differentiation during helminth infection and allergic asthma.
Nature communications
2017
Workshop Report: Modulation of Antitumor Immune Responses by Dietary and Microbial Metabolites.
Journal of the National Cancer Institute
2017
The Aryl Hydrocarbon Receptor Preferentially Marks and Promotes Gut Regulatory T Cells.
Cell reports
2017
Optimized multiplex immunofluorescence single-cell analysis reveals tuft cell heterogeneity.
JCI insight
2017
Novel insights into microbiome in colitis and colorectal cancer.
Current opinion in gastroenterology
2017
Microbiota as a mediator of cancer progression and therapy.
Translational research : the journal of laboratory and clinical medicine
2017
Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis.
Cancer research
2017
Human Intestinal Microbiota and Colorectal Cancer: Moving Beyond Associative Studies.
Gastroenterology
2017
ClbM is a versatile, cation-promiscuous MATE transporter found in the colibactin biosynthetic gene cluster.
Biochemical and biophysical research communications
2017
Carcinogenesis and therapeutics: the microbiota perspective.
Nature microbiology
2017
Cancer treatment: Bacterial snack attack deactivates a drug.
Nature
2016
The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals.
Cell reports
2016
Murine Model of Intestinal Ischemia-reperfusion Injury.
Journal of visualized experiments : JoVE
2016
Microbiota and host immune responses: a love-hate relationship.
Immunology
2016
MATE transport of the E. coli-derived genotoxin colibactin.
Nature microbiology
2016
Intestinal Microbiota in Inflammatory Bowel Disease and Carcinogenesis: Implication for Therapeutics.
Clinical pharmacology and therapeutics
2016
High purity galacto-oligosaccharides enhance specific Bifidobacterium species and their metabolic activity in the mouse gut microbiome.
Beneficial microbes
2016
Gut Microbiota and a Selectively Bred Taste Phenotype: A Novel Model of Microbiome-Behavior Relationships.
Psychosomatic medicine
2016
Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn's disease.
Nature communications
2016
A Rapid Screenable Assay for Compounds That Protect Against Intestinal Injury in Zebrafish Larva.
Methods in molecular biology (Clifton, N.J.)
2015
The Role of Curcumin in Modulating Colonic Microbiota During Colitis and Colon Cancer Prevention.
Inflammatory bowel diseases
2015
The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?
Trends in cancer
2015
SCFAs Take a Toll En Route to Metabolic Syndrome.
Cell metabolism
2015
Professor Arlette Darfeuille-Michaud: the discovery of adherent-invasive Escherichia coli.
Journal of Crohn's & colitis
2015
Partial Depletion of the Proinflammatory Monocyte Population Is Neuroprotective in the Myenteric Plexus But Not in the Basal Ganglia in a Mptp Mouse Model of Parkinson's Disease
Brain Behavior and Immunity
2015
Microbial activities and intestinal homeostasis: A delicate balance between health and disease.
Cellular and molecular gastroenterology and hepatology
2015
Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt.
Nature medicine
2015
Differential Relevance of NF-κB and JNK in the Pathophysiology of Hemorrhage/Resususcitation-Induced Liver Injury after Chronic Ethanol Feeding.
PloS one
2014
Time To Enlist Life-Saving, Gutsy Allies
New Scientist
2014
The microbiota protects against ischemia/reperfusion-induced intestinal injury through nucleotide-binding oligomerization domain-containing protein 2 (NOD2) signaling.
The American journal of pathology
2014
Protective mucosal immunity mediated by epithelial CD1d and IL-10.
Nature
2014
Nucleotide-binding oligomerization domain-containing protein 2 controls host response to Campylobacter jejuni in Il10-/- mice.
The Journal of infectious diseases
2014
Microbial-derived butyrate: an oncometabolite or tumor-suppressive metabolite?
Cell host & microbe
2014
Microbial imbalance and intestinal pathologies: connections and contributions.
Disease models & mechanisms
2014
Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer.
Nature communications
2014
Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain – a randomised clinical study.
Alimentary pharmacology & therapeutics
2014
Gut commensal bacteria and regional Wnt gene expression in the proximal versus distal colon.
The American journal of pathology
2014
GPR109a: the missing link between microbiome and good health?
Immunity
2014
Glass Microparticulate Ingestion: An Unusual And Difficult-To-Diagnose Cause Of Chronic Abdominal Pain.
Acg Case Reports Journal
2014
Fusobacterium and Enterobacteriaceae: important players for CRC?
Immunology letters
2014
From promotion to management: the wide impact of bacteria on cancer and its treatment.
BioEssays : news and reviews in molecular, cellular and developmental biology
2014
Do bugs define cancer geography?
The Journal of experimental medicine
2014
Could a swimming creature inform us on intestinal diseases? Lessons from zebrafish.
Inflammatory bowel diseases
2014
Commensal microbiota stimulate systemic neutrophil migration through induction of serum amyloid A.
Cellular microbiology
2014
Chronic Ethanol Feeding Modulates Inflammatory Mediators, Activation Of Nuclear Factor-Κb, And Responsiveness To Endotoxin In Murine Kupffer Cells And Circulating Leukocytes.
Mediators of Inflammation
2014
Chemotherapy, immunity and microbiota–a new triumvirate?
Nature medicine
2014
Bugs and food: a recipe for cancer?
Cell metabolism
2013
VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer.
Scientific reports
2013
The microbiome and cancer.
Nature reviews. Cancer
2013
The complex interplay between inflammation, the microbiota and colorectal cancer.
Gut microbes
2013
Stochastic changes over time and not founder effects drive cage effects in microbial community assembly in a mouse model.
The ISME journal
2013
Phosphatidylinositol 3-kinase-γ signaling promotes Campylobacter jejuni-induced colitis through neutrophil recruitment in mice.
Journal of immunology (Baltimore, Md. : 1950)
2013
Oxymatrine prevents NF-κB nuclear translocation and ameliorates acute intestinal inflammation.
Scientific reports
2013
Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer.
Immunity
2013
Microbial Influence On Colorectal Cancer
Digestive Diseases and Sciences
2013
Intestinal epithelial cell-derived μ-opioid signaling protects against ischemia reperfusion injury through PI3K signaling.
The American journal of pathology
2013
Glafenine-induced intestinal injury in zebrafish is ameliorated by μ-opioid signaling via enhancement of Atf6-dependent cellular stress responses.
Disease models & mechanisms
2013
Epithelial cell-specific MyD88 signaling mediates ischemia/reperfusion-induced intestinal injury independent of microbial status.
Inflammatory bowel diseases
2013
Diet, microbiome, and the intestinal epithelium: an essential triumvirate?
BioMed research international
2013
Colorectal cancer: looking for answers in the microbiota.
Cancer discovery
2013
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda.
Inflammatory bowel diseases
2013
Activation of NF-κB after chronic ethanol intake and haemorrhagic shock/resuscitation in mice.
British journal of pharmacology
2012
Time dependency and topography of hepatic nuclear factor κB activation after hemorrhagic shock and resuscitation in mice.
Shock (Augusta, Ga.)
2012
Think small: zebrafish as a model system of human pathology.
Journal of biomedicine & biotechnology
2012
The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction.
Immunity
2012
The microbiota is essential for the generation of black tea theaflavins-derived metabolites.
PloS one
2012
Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes.
Investigative ophthalmology & visual science
2012
Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis.
PloS one
2012
NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling.
Immunity
2012
Mouse background strain profoundly influences Paneth cell function and intestinal microbial composition.
PloS one
2012
Intestinal inflammation targets cancer-inducing activity of the microbiota.
Science (New York, N.Y.)
2012
Colorectal cancer: CRC–all about microbial products and barrier function?
Nature reviews. Gastroenterology & hepatology
2012
Campylobacter jejuni induces colitis through activation of mammalian target of rapamycin signaling.
Gastroenterology
2012
A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis.
PloS one
2011
The struggle within: microbial influences on colorectal cancer.
Inflammatory bowel diseases
2011
The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells.
Shock (Augusta, Ga.)
2011
Structural identification of mouse fecal metabolites of theaflavin 3,3'-digallate using liquid chromatography tandem mass spectrometry.
Journal of chromatography. A
2011
Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.
American journal of physiology. Gastrointestinal and liver physiology
2011
PI3K-dependent GSK3ß(Ser9)-phosphorylation is implicated in the intestinal epithelial cell wound-healing response.
PloS one
2011
Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling.
The American journal of pathology
2011
Microbial colonization induces dynamic temporal and spatial patterns of NF-κB activation in the zebrafish digestive tract.
Gastroenterology
2011
Gut microbiota and probiotics in colon tumorigenesis.
Cancer letters
2011
Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis.
Inflammatory bowel diseases
2010
Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis.
Gastroenterology
2010
The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer.
The Journal of experimental medicine
2010
Probiotics and ileitis: could augmentation of TNF/NFκB activity be the answer?
Gut microbes
2010
MyD88 signaling in the intestine: Dr Jekyll and Mr Hyde?
Gastroenterology
2010
High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse.
PloS one
2010
Downregulation of aging-related Klotho gene in experimental colitis: the role of TNF and IFNGamma
Gastroenterology
2010
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.
Science (New York, N.Y.)
2009
Wound Healing Responses At The Gastrointestinal Epithelium: A Close Look At Novel Regulatory Factors And Investigative Approaches.
Zeitschrift Fur Gastroenterologie
2009
Tomato lycopene extract prevents lipopolysaccharide-induced NF-kappaB signaling but worsens dextran sulfate sodium-induced colitis in NF-kappaBEGFP mice.
PloS one
2009
Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility.
PloS one
2009
Microbes And Colorectal Cancer: Is There A Relationship?
Current Oncology (Toronto, Ont.)
2009
Intestinal epithelial-derived TAK1 signaling is essential for cytoprotection against chemical-induced colitis.
PloS one
2009
Gnotobiotic IL-10; NF-kappaB mice develop rapid and severe colitis following Campylobacter jejuni infection.
PloS one
2008
Toll-like receptor 9-dependent macrophage activation by Entamoeba histolytica DNA.
Infection and immunity
2008
Regulation and functional impact of lipopolysaccharide induced Nod2 gene expression in the murine epididymal epithelial cell line PC1.
Immunology
2008
NF-kappaB and the intestine: friend or foe?
Inflammatory bowel diseases
2008
Nf-kappa B signaling cascade and IBD: turn it down?
Inflammatory bowel diseases
2008
Limited Effects Of Dietary Curcumin On Th-1 Driven Colitis In Il-10 Deficient Mice Suggest An Il-10-Dependent Mechanism Of Protection.
American Journal of Physiology-Gastrointestinal and Liver Physiology
2008
Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer.
Molecular pharmacology
2008
Impaired Bcl3 up-regulation leads to enhanced lipopolysaccharide-induced interleukin (IL)-23P19 gene expression in IL-10(-/-) mice.
The Journal of biological chemistry
2008
Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis.
Journal of immunology (Baltimore, Md. : 1950)
2007
The flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective molecules.
PloS one
2007
Gnotobiotic IL-10-/-;NF-kappa B(EGFP) mice reveal the critical role of TLR/NF-kappa B signaling in commensal bacteria-induced colitis.
Journal of immunology (Baltimore, Md. : 1950)
2007
Dual-association of gnotobiotic IL-10-/- mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis.
Inflammatory bowel diseases
2007
Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide.
Journal of immunology (Baltimore, Md. : 1950)
2006
Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes.
Journal of cellular physiology
2006
Critical role for H3 phosphorylation and p38-MAPK pathway in intestinal wound-healing response
American Journal of Physiology-Cell Physiology
2005
Ubiquitin protein modification and signal transduction: implications for inflammatory bowel diseases.
Inflammatory bowel diseases
2005
Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2.
The Journal of biological chemistry
2005
The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells.
Immunology
2005
STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells.
Blood
2005
Serum amyloid A activates NF-kappaB and proinflammatory gene expression in human and murine intestinal epithelial cells.
European journal of immunology
2005
Salvia Miltiorrhiza Water-Soluble Extract, But Not Its Constituent Salvianolic Acid B, Abrogates Lps-Induced Nf-Kappab Signalling In Intestinal Epithelial Cells.
Clinical and Experimental Immunology
2005
Regulation Of Tnf-Related Apoptosis-Inducing Ligand-Mediated Death-Signal Pathway In Human Beta Cells By Fas-Associated Death Domain And Nuclear Factor Kappab.
Human Immunology
2005
Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory phenotype that attenuates glomerular inflammation in vivo.
The American journal of pathology
2005
Adenosine is a negative regulator of NF-kappaB and MAPK signaling in human intestinal epithelial cells.
Cellular immunology
2005
Activation of NF-kappaB following detachment delays apoptosis in intestinal epithelial cells.
Oncogene
2004
Role of NF-kappaB in inflammatory disorders: just when you thought you knew everything!
Journal of pediatric gastroenterology and nutrition
2004
NF-kappaB-inducing kinase restores defective IkappaB kinase activity and NF-kappaB signaling in intestinal epithelial cells.
Cellular signalling
2004
NF-kappaB inducing kinase activates NF-kappaB transcriptional activity independently of IkappaB kinase gamma through a p38 MAPK-dependent RelA phosphorylation pathway.
Cellular signalling
2004
Loss Of E-Cadherin Leads To Upregulation Of Nfkappab Activity In Malignant Melanoma.
Oncogene
2004
Interaction between resident luminal bacteria and the host: can a healthy relationship turn sour?
Journal of pediatric gastroenterology and nutrition
2004
In vivo pattern of lipopolysaccharide and anti-CD3-induced NF-kappa B activation using a novel gene-targeted enhanced GFP reporter gene mouse.
Journal of immunology (Baltimore, Md. : 1950)
2004
Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells.
Journal of cellular physiology
2004
Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells.
American journal of physiology. Gastrointestinal and liver physiology
2004
Differential Effect Of Immune Cells On Non-Pathogenic Gram-Negative Bacteria-Induced Nuclear Factor-Kappab Activation And Pro-Inflammatory Gene Expression In Intestinal Epithelial Cells.
Immunology
2003
Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation.
The Journal of biological chemistry
2003
Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.
Hepatology (Baltimore, Md.)
2003
Intestinal epithelial cells and innate immunity in the intestine: is CARD15/Nod2 another player?
Gastroenterology
2003
Butyrate modulates intestinal epithelial cell-mediated neutrophil migration.
Clinical and experimental immunology
2002
IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines.
The Journal of biological chemistry
2002
Differential requirement for NF-kappaB-inducing kinase in the induction of NF-kappaB by IL-1beta, TNF-alpha, and Fas.
American journal of physiology. Cell physiology
2002
Constitutive nuclear factor-kappa B activity is required for central neuron survival.
The Journal of neuroscience : the official journal of the Society for Neuroscience
2001
Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells.
Gastroenterology
2001
Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis.
Diabetes
2001
Cryptosporidium parvum activates nuclear factor kappaB in biliary epithelia preventing epithelial cell apoptosis.
Gastroenterology
2000
The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection.
American journal of physiology. Cell physiology
2000
NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases.
Inflammatory bowel diseases
2000
Cellular differentiation causes a selective down-regulation of interleukin (IL)-1beta-mediated NF-kappaB activation and IL-8 gene expression in intestinal epithelial cells.
The Journal of biological chemistry
1999
Tnf Receptor-Associated Factor-2 Is Involved In Both Il-1 Beta And Tnf-Alpha Signaling Cascades Leading To Nf-Kappa B Activation And Il-8 Expression In Human Intestinal Epithelial Cells.
Journal of immunology (Baltimore, Md. : 1950)
1999
Suppression Of Nf-Kappab-Dependent Proinflammatory Gene Expression In Human Rpe Cells By A Proteasome Inhibitor.
Investigative Ophthalmology & Visual Science
1999
Molecular and cellular biology of the small intestine.
Current opinion in gastroenterology
1999
Curcumin Blocks Cytokine-Mediated Nf-Kappa B Activation And Proinflammatory Gene Expression By Inhibiting Inhibitory Factor I-Kappa B Kinase Activity.
Journal of immunology (Baltimore, Md. : 1950)
1998
Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells.
Immunology
1998
Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors.
Gut
1998
Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells.
Journal of immunology (Baltimore, Md. : 1950)
1998
Inhibition Of Nfkappab In Activated Rat Hepatic Stellate Cells By Proteasome Inhibitors And An Ikappab Super-Repressor.
Hepatology
1998
Differential Expression Of Interleukin 1 Receptor Antagonist Isoforms In Human Intestinal Epithelial Cells.
Gastroenterology
1998
Cytokines induce NF-kappaB in activated but not in quiescent rat hepatic stellate cells.
The American journal of physiology
1997
Evidence For Altered Regulation Of I Kappa B Alpha Degradation In Human Colonic Epithelial Cells.
Journal of immunology (Baltimore, Md. : 1950)
1997
Differential Effects Of Cell Density On 5-Lipoxygenase (5-Lo), Five-Lipoxygenase-Activating Protein (Flap) And Interleukin-1 Beta (Il-1 Beta) Expression In Human Neutrophils.
Inflammation
1991
Differential Synthesis Of 5-Lipoxygenase In Peripheral Blood And Synovial Fluid Neutrophils In Rheumatoid Arthritis.
Journal of immunology (Baltimore, Md. : 1950)

Grants:

Apr 2024 ACTIVE
UF Health Cancer Center Bridge Seed Grant (Continued)
UF HEALTH SHANDS HOSPITAL · Project Manager

Oct 2023 ACTIVE
The Gastrointestinal Microbiota and Breast Cancer
MEDICAL COLLEGE OF VIRGINIA FOUNDATION · Project Manager

Jun 2023 ACTIVE
UF Health Cancer Center Support Grant
NATL INST OF HLTH NCI · Other

May 2023 ACTIVE
Microbiota, Metabolites, and Colon Neoplasia
UNIV OF CONNECTICUT · Principal Investigator

Mar 2023 ACTIVE
Chemical Approaches Toward the Identification, Functional Analysis and Biosynthesis of Small Molecule Cyclomodulins
YALE UNIV · Principal Investigator

Feb 2023 ACTIVE
Deciphering microbial contribution to androgen bioavailability in castration resistant prostate cancer patients
NATL INST OF HLTH NCI · Principal Investigator

Jul 2022 ACTIVE
Microbiota-mediated enhancement of the anti-tumor effect of natural killer cells
NATL INST OF HLTH NCI · Principal Investigator

May 2022 ACTIVE
Bacteriophage-mediated microbiota modification to prevent colorectal cancer development
NATL INST OF HLTH NCI · Principal Investigator

Dec 2021 ACTIVE
Bacteriophages as Modulators of Bacterial Colonization
NATL INST OF HLTH NIAID · Other

Aug 2021 ACTIVE
Role of RORgt+ (note: g: is gamma symbol) lymphocytes in Gut Tissue Homeostasis
NATL INST OF HLTH NIAID · Co-Investigator

Jul 2021 – Jun 2024
Exploiting microbiota metabolism for colorectal cancer prevention
YALE UNIV · Principal Investigator

Jun 2021 – Nov 2023
Modulation of microbiome function by host-derived noncoding small RNA
NATL INST OF HLTH NIAID · Principal Investigator

Mar 2019 – Nov 2023
Role of the microbiota in DNA methylation and CRC development
CORIELL INSTITUTE FOR MEDICAL RESEARCH · Principal Investigator

Jan 2019 – Nov 2024
Human milk metabolomics and microbe-host interactions associated with pediatric obesity
NATL INST OF HLTH NIDDK · Other

Jul 2018 ACTIVE
Role of Bacteria in Colitis-Associated Colon Cancer
NATL INST OF HLTH NIDDK · Principal Investigator

Jan 2018 – Dec 2023
The role of the microbiome on pancreatic carcinogenesis in a murine model
AMERICAN CANCER SOCIETY · Other

Dec 2017 – Feb 2019
Role of the microbiota in DNA methylation and CRC development
TEMPLE UNIVERSITY · Principal Investigator

Dec 2017 – Feb 2023
Chemical approaches toward the identification, functional analysis, and biosynthesis of small molecule cyclomodulin
YALE UNIV · Principal Investigator

Oct 2016 – Sep 2018
Role of Gram negative bacterial lipopolysaccharide in CXCR4-mediated pancreatic carcinogenesis
ASSOC OF VA SURGEONS FOU · Faculty

Aug 2016 – Dec 2021
ACE2, Brain, Gut Dysbiosis in Pulmonary Hypertension
NATL INST OF HLTH NHLBI · Co-Investigator

Jul 2016 – Jun 2019
Impact of host signaling on microbial activities in the development of colitis-associated colorectal cancer
CROHNS & COLITIS FOUNDATION · Other

Apr 2016 – Sep 2021
Brain-Gut Microbiome-Immune Axis in Hypertension
NATL INST OF HLTH NHLBI · Project Manager

Dec 2015 – Nov 2019
Mechanism by which H2S-producing bacteria influence development of colorectal cancer
NATL INST OF HLTH NCI · Principal Investigator

Jul 2015 – Jun 2024
Florida Academic Cancer Center Alliance Seed Grants
UF HEALTH SHANDS HOSPITAL · Project Manager

Jun 2015 – Nov 2017
Microbial Factors Implicated in the Development of Colorectal Cancer
UF DSR OPPORTUNITY FUND · Principal Investigator

Feb 2015 – Oct 2023
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
UF HEALTH SHANDS HOSPITAL · Project Manager

Jan 2015 – Dec 2021
Impact of microbiota-mediated biotransformation of black tea polyphenols on GI health
NATL CTR FOR COMPLEM AND INTEGRATIVE HLT · Principal Investigator

May 2014 – May 2019
Multiple Sponsors
MULTIPLE SPONSORS · Principal Investigator

Jul 2013 – Jun 2016
Regulation of Immunosuppressive Molecules in IBD
NATL INST OF HLTH NIDDK · Principal Investigator

Jul 2013 – Mar 2018
Role of Bacteria in Colitis-Associated Colon Cancer
NATL INST OF HLTH NIDDK · Principal Investigator

Jul 2013 – Jun 2021
Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
FL DEPT OF HLTH · Project Manager

Patents:

Issued June 2023
Perfusion Enabled Bioreactors
#11,680,241
Published March 2023
Compositions and Methods for Modulation of Bacterial Gene Expression
#US-2023-0381104-A1

Full Profile

Elias Sayour MD, PhD

Stop Children’s Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research; Assistant Dean

Department: MD-NEUROLOGICAL SURGERY

Mailing Address:: PO BOX 100265
PO BOX 100265
DEPARTMENT OF NEUROSURGERY
GAINESVILLE FL 326100265

Physical Address:: L2-100
1149 Newell Dr.
GAINESVILLE FL 32611

Elias Sayour, MD, PhD, is the Stop Children’s Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research in the UF departments of neurosurgery and pediatrics at the University of Florida. He is also a principal investigator of the ribonucleic acid engineering laboratory at the Preston A. Wells, Jr. Center for Brain Tumor Therapy. He received his bachelor’s degree from Fordham University, his medical degree from the University of Buffalo and his doctorate from Duke University.

He completed his residency in pediatrics at Cohen’s Children’s Medical Center in New York and his fellowship at Duke University Medical Center. During his fellowship training, he completed a two-year National Institutes of Health research fellowship in cancer biology and developmental therapeutics. His primary research focus is developing tumor RNA loaded nanocarriers to re-direct host immunity against pediatric brain tumors.

Dr. Sayour is an NIH-funded investigator focused on on developing new nanotech vaccines to reprogram the immune system against cancer cells. He is investigating the use of personalized nanoparticles small enough to deliver essential information to the immune system educating it reject pediatric cancer. Currently his group is investigating the safety and efficacy of this novel vaccine formulation in canines with malignant brain tumors before translation into dedicated human studies.

Dr. Sayour’s work has been nationally recognized by the American Society of Pediatric Hematology-Oncology, National Institutes of Health, and U.S. Department of Defense. He has been the recipient of the Hyundai Hope on Wheels Hope Award, St. Baldrick’s Scholar Award, and the American Brain Tumor Association Discovery Award.

Dr. Sayour is board-certified in general pediatrics and pediatric hematology-oncology.

He has presented his work at several national meetings and is a member of the Children’s Oncology Group, Society of Neuro-Oncology and the American Society of Pediatric Hematology-Oncology.

Certifications:

Hematology-Oncology
American Board of Pediatrics
Pediatrics
American Board of Pediatrics

Specialties:

Neurosurgery
Pediatrics

Subspecialties:

Pediatric Hematology-Oncology

Clinical Interests:

Brain tumor – children

Research Summary:

Research Interests:

Immunotherapeutics for CNS malignancies
Pediatric brain tumors

Publications:

2024
Vaccines: a promising therapy for myelodysplastic syndrome.
Journal of hematology & oncology
2024
RNA aggregates harness the danger response for potent cancer immunotherapy.
Cell
2024
Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen-presenting cells.
Molecular therapy. Methods & clinical development
2024
Development of a murine laser interstitial thermotherapy system.
Neurosurgical focus
2024
Cancer mRNA vaccines: clinical advances and future opportunities.
Nature reviews. Clinical oncology
2023
Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology.
Neoplasia (New York, N.Y.)
2023
Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor – Chimeric Antigen Receptor T cell interactions.
bioRxiv : the preprint server for biology
2023
Spotlighting cellular therapies to advance the treatment of medulloblastoma.
Neuro-oncology
2023
mRNA aggregates harness danger response for potent cancer immunotherapy.
medRxiv : the preprint server for health sciences
2023
Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.
Journal of applied statistics
2023
Bioconjugation of COL1 protein on liquid-like solid surfaces to study tumor invasion dynamics.
Biointerphases
2023
Bioconjugated liquid-like solid enhances characterization of solid tumor – chimeric antigen receptor T cell interactions.
Acta biomaterialia
2023
Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma.
Cancers
2022
The current landscape of immunotherapy for pediatric brain tumors.
Nature cancer
2022
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1).
Neoplasia (New York, N.Y.)
2022
Evolution and Revolution of Imaging Technologies in Neurosurgery.
Neurologia medico-chirurgica
2022
Contemporary RNA Therapeutics for Glioblastoma.
Neuromolecular medicine
2022
CAR T Cell Locomotion in Solid Tumor Microenvironment.
Cells
2021
Optimizing T Cell-Based Therapy for Glioblastoma.
Frontiers in immunology
2021
Nanoparticles as immunomodulators and translational agents in brain tumors.
Journal of neuro-oncology
2021
GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction.
Translational oncology
2021
Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Veterinary immunology and immunopathology
2020
GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.
American journal of cancer research
2020
Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma.
Cancer research
2019
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling.
Journal for immunotherapy of cancer
2019
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.
Molecular therapy : the journal of the American Society of Gene Therapy
2019
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Neuro-oncology
2019
Emerging trends in immunotherapy for pediatric sarcomas.
Journal of hematology & oncology
2019
Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.
ACS nano
2019
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Nature communications
2019
Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy.
Veterinary immunology and immunopathology
2018
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.
Frontiers in molecular neuroscience
2018
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Nano letters
2018
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.
The EMBO journal
2018
CD70, a novel target of CAR T-cell therapy for gliomas.
Neuro-oncology
2018
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
International journal of molecular sciences
2017
Translational nanoparticle engineering for cancer vaccines.
Oncoimmunology
2017
The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma.
Journal of neurosurgery
2017
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.
Oncoimmunology
2017
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
Journal of immunology research
2017
Immunotherapy for Pediatric Brain Tumors.
Brain sciences
2017
CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression.
Frontiers in immunology
2016
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
Cancer immunology, immunotherapy : CII
2016
FGFR1 N546K and H3F3A K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers.
Histopathology
2016
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
2016
Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia.
Pediatric blood & cancer
2015
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Cancer immunology research
2015
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.
Oncoimmunology
2015
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
Cancer immunology, immunotherapy : CII
2015
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.
Journal for immunotherapy of cancer
2015
A novel ELANE gene mutation in a patient with severe congenital neutropenia and intermittent thrombocytopenia.
Pediatric blood & cancer
2014
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
PloS one
2013
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer immunology, immunotherapy : CII

Grants:

Sep 2024 ACTIVE
Targeted RNA-Lipid Particle Aggregates in Pediatric Oncology: A Novel Therapeutic Strategy for Fibrolamellar Hepatocellular Carcinoma
HYUNDAI HOPE ON WHEELS · Other

May 2024 – Jul 2024
Pediatric Oncology Student Training (POST) Program
ALEXS LEMONADE STAND FOUNDATION · Principal Investigator

May 2024 ACTIVE
Combining Epigenetic Therapy and Immunotherapy to Target Group 4 Medulloblastoma
CHILDRENS RESEARCH INSTITUTE · Project Manager

May 2024 ACTIVE
B7-H3-CAR iNKT Therapy for High Risk Medulloblastoma
NATL PEDIATRIC CANCER FOU · Principal Investigator

Apr 2024 ACTIVE
Targeting Glycogen Metabolism in Ewing's Sarcoma: Diagnostic, Prognostic, and Therapeutic Applications
NATL INST OF HLTH NCI · Co-Investigator

Feb 2024 ACTIVE
RNA-nanoparticle (RNA-NP) vaccine for ARMS
KATE AMATO FOUNDATION · Other

Jul 2023 – Jun 2024
Studying the impact of RNA-nanoparticle vaccine on immune response to DIPG/DMG
DIPG DMG RESEARCH FUNDING ALLIANCE · Other

Jul 2023 ACTIVE
Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)
STANFORD UNIV · Other

Jul 2023 ACTIVE
Nanoparticle vaccines targeting metastatic osteosarcoma
OSTEOSARCOMA INSTITUTE · Principal Investigator

Jun 2023 ACTIVE
UF Health Cancer Center Support Grant
NATL INST OF HLTH NCI · Other

Apr 2023 ACTIVE
Phase I/II clinical trial for malignant pediatric gliomas using 8R-70CAR T cells
FL DEPT OF HLTH LIVE LIKE BELLA · Co-Investigator

Feb 2023 ACTIVE
An RNA-based nanoparticle vaccine approach for the prevention and treatment of C9orf72 ALS/FTD
US ARMY MED RES ACQUISITION · Co-Project Director/Principal Investigator

Jan 2023 ACTIVE
Phase I trial of multilamellar mRNA lipid particles for recurrent pediatric high-grade glioma
ALEXS LEMONADE STAND FOUNDATION · Principal Investigator

Jan 2023 – Dec 2024
Investigating the Immune Response to RNA-lipid Nanoparticle Vaccines in a Clinical Trial for Canines with Osteosarcoma
PEDIATRIC CANCER RESEARCH FOU · Other

Dec 2022 ACTIVE
Establishment of 3D metastatic osteosarcoma organoid model to accelerate combination immunotherapy
HYUNDAI HOPE ON WHEELS · Other

Nov 2022 – Apr 2024
Determining and enhancing stability of RNA-nanoparticle vaccines for a multi-center NPCF clinical trial for patients with metastatic osteosarcoma
NATL PEDIATRIC CANCER FOU · Other

Sep 2022 ACTIVE
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles
NATL INST OF HLTH NCI · Principal Investigator

Aug 2022 ACTIVE
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 05/21/2020
US FOOD AND DRUG ADMN · Principal Investigator

Jul 2022 ACTIVE
Leveraging RNA-lipid nanoparticle vaccines to induce immune response in metastatic pulmonary osteosarcoma
THE V FOU FOR CANCER RESEARCH · Co-Investigator

May 2022 ACTIVE
Patterns of resistance to initial therapeutic treatment in Ewings Sarcoma
Hematology/Oncology Pharmacy Asso Fou · Co-Investigator

Apr 2022 ACTIVE
Unlocking CAR T cell efficacy against osteosarcoma using adjuvant RNA vaccine
FL DEPT OF HLTH LIVE LIKE BELLA · Other

Apr 2022 ACTIVE
Novel RNA-Nanoparticle vaccine for treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy
FL DEPT OF HLTH BIOMED RES PGM/J&E KING · Co-Investigator

Feb 2022 – Jun 2022
A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Feb 2022 ACTIVE
A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Jan 2022 – Jun 2023
Development of RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
H LEE MOFFITT CANCER CTR & RES INST · Principal Investigator

Jan 2022 – Dec 2024
Development of RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
NATL PEDIATRIC CANCER FOU · Principal Investigator

Oct 2021 – Apr 2023
Pan-Neoantigen Targeted RNA-nanoparticles for Recurrent Pulmonary Osteosarcoma
CHANCE FOR LIFE FOUNDATION · Principal Investigator

Sep 2021 – Aug 2024
Immune correlate studies in pediatric high-grade glioma patients receiving RNA nanoparticle vaccines
TEAM JACK FOUNDATION · Principal Investigator

Jul 2021 – Aug 2022
Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
Rally Foundation · Principal Investigator

Apr 2021 ACTIVE
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis
NATL INST OF HLTH NCI · Co-Investigator

Feb 2021 ACTIVE
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
NATL INST OF HLTH NCI · Principal Investigator

Feb 2021 ACTIVE
PNOC 021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Jan 2021 ACTIVE
A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Jul 2020 ACTIVE
Pediatric Brain Tumor ConsortiumA multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors
ST JUDE CHILDRENS RESEARCH HOSPITAL · Principal Investigator

Jul 2020 – Jul 2021
Remodeling Host Immunity in Oral Cancer with Personalized RNA Nanoparticle Vaccines
NATL INST OF HLTH NIDCR · Other

Jul 2020 – Jun 2024
Translating Personalized RNA Nanoparticle Vaccines for Oral Cancer
OCALA ROYAL DAMES FOR CANCER RESEARCH · Principal Investigator

Jul 2020 – Dec 2024
RNA-nanoparticle vaccines for pediatric high-grade glioma
CURESEARCH FOR CHILDRENS CANCER · Principal Investigator

Jun 2020 – Nov 2023
Novel immunologic therapy of soft tissue sarcoma
FL DEPT OF HLTH LIVE LIKE BELLA · Co-Investigator

Jun 2020 – May 2023
Lipidnanoparticle vaccines targeting metastatic lung cancer from osteosarcoma
FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE · Principal Investigator

Jun 2020 – Nov 2023
Multi-center phase I study evaluating lipid-nanoparticle vaccines against pediatric high-grade glioma
FL DEPT OF HLTH LIVE LIKE BELLA · Principal Investigator

Jun 2020 ACTIVE
A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
DANA FARBER CANCER INST · Principal Investigator

May 2020 – Jan 2022
A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Dec 2019 – Jun 2022
Nanoparticles targeting genetic translocations in pediatric brain tumors
HYUNDAI HOPE ON WHEELS · Principal Investigator

Sep 2019 – Sep 2024
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
ICON CLINICAL RESEARCH INC · Principal Investigator

Aug 2019 ACTIVE
A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intristic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Jul 2019 – Dec 2020
Re-programming immunity to target mutations across medulloblastoma subtypes
ST BALDRICKS FOUNDATION · Principal Investigator

Jul 2019 – Sep 2021
Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
Rally Foundation · Principal Investigator

Mar 2019 – Aug 2024
CTOA
UNIV OF FLORIDA · Principal Investigator

Jan 2019 – Dec 2023
Development of personalized RNA loaded nano particles for children with refractory solid tumors.
UF FOUNDATION · Principal Investigator

Dec 2018 – Mar 2022
A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High Grade Glioma (Excluding Diffuse Intrinsic Pontine Glioma)
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Jul 2018 – Jun 2020
Host Immunomodulatory RNA-nanoparticles targeting malignant canine glioma
UF FOUNDATION · Principal Investigator

Jul 2018 – Dec 2021
Legacy Foundation
UF FOUNDATION · Project Manager

Jul 2018 ACTIVE
Florida Center for Brain Tumor Research
FL DEPT OF HLTH · Project Manager

Mar 2018 – Nov 2022
Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E – or BRAF Ins T mutant Brain Tumors
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Jan 2018 – Jun 2020
Development of Personalized RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
H LEE MOFFITT CANCER CTR & RES INST · Principal Investigator

Dec 2017 – Nov 2024
Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
UNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator

Nov 2017 ACTIVE
Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I)
H LEE MOFFITT CANCER CTR & RES INST · Principal Investigator

Sep 2017 – Sep 2020
RNA-nanoparticles targeting H3.3 K27M epitopes in diffuse intrinsic pontine glioma
US ARMY MED RES ACQUISITION · Principal Investigator

Sep 2017 – Jun 2021
UFHCC Triple Negative Breast Cancer (TNBC) Pilot Project Program
MULTIPLE SPONSORS · Project Manager

Jul 2017 – Dec 2019
Immunotherapeutic targeting of osteosarcoma neoantigens
Rally Foundation · Principal Investigator

May 2017 – Feb 2023
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies
BRISTOL MYERS SQUIBB CO · Principal Investigator

Apr 2017 – Jun 2021
OoR CTSI Institutional Matching Support
UF DIV OF SPONSORED RES MATCHING FUNDS · Project Manager

Nov 2016 – Nov 2024
Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single-Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
NATIONWIDE CHILDRENS HOSPITAL · Principal Investigator

Sep 2016 ACTIVE
A Clinical and Molecular Risk-directed Therapy for Newly Diagnosed Medulloblastoma
ST JUDE CHILDRENS RESEARCH HOSPITAL · Principal Investigator

Sep 2016 – Aug 2021
Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting Glioblastoma
NATL INST OF HLTH NCI · Principal Investigator

Jul 2016 – Jun 2020
RNA nanoparticle vaccines targeting malignant canine gliomas
OCALA ROYAL DAMES FOR CANCER RESEARCH · Principal Investigator

Jul 2016 – Jun 2020
Re-programming immunity to target mutations across medulloblastoma subtypes
ST BALDRICKS FOUNDATION · Principal Investigator

Apr 2016 – Mar 2018
Re-programming osteosarcoma immune evasion with CAR modified T cells
UF FOUNDATION · Principal Investigator

Jul 2015 – Jun 2024
Florida Academic Cancer Center Alliance Seed Grants
UF HEALTH SHANDS HOSPITAL · Project Manager

Dec 2014 – Jun 2017
Efficacious, Translational and Personalized RNA-nanoparticle Vaccines Targeting Pediatric Brain Tumors
HYUNDAI HOPE ON WHEELS · Principal Investigator

Jul 2013 – Jun 2021
Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
FL DEPT OF HLTH · Project Manager

Patents:

Published May 2023
Materials and Methods for Sensitizing Tumors to Immune Response
#2023-0414721-A1
Published September 2022
Multilamellar RNA Nanoparticle Vaccine Against SARS-COV-2
#US-2023-0226169-A1
Published August 2022
Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
#US-2023-0346700-A1
Published August 2022
RNA-Loaded Nanoparticles and Use Thereof for the Treatment of Cancer
#US-2023-0096704-A1
Published October 2021
Compositions for Treatment of Diffuse Intrinsic Pontine Glioma
#US-2022-0218808-A1
Published February 2021
Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
#US-2021-0170005-A1
Published November 2020
Magnetic Liposomes and Related Treatment and Imaging Methods
#US-2021-0077399-A1
Published February 2020
A Monophosphoryl Lipid A Liposome Based Cancer Vaccine
#US-2022-0133872-A1

Education:

2013
Fellowship – Pediatric Hematology/Oncology
Duke University Medical Center
2012-2015
Ph.D.
Duke University
2010
Residency – Pediatrics
Long Island Jewish Medical Center
2007
M.D.
University at Buffalo
2003
B.S.
Fordham University

Full Profile